Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

January 8th 2021

BTK Monotherapy for Frontline CLL

January 8th 2021

Selecting Frontline Therapy to Treat CLL

January 8th 2021

Dr. Hobbs on Choosing Optimal Second-Line Treatment Option for TKI-Resistant CLL

January 7th 2021

Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.

Dr. Barr on Exploring U2 Plus Venetoclax in Relapsed/Refractory CLL

January 4th 2021

Paul M. Barr, MD, discusses exploring umbralisib plus ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Next Steps of the CLL14 Trial in CLL

January 4th 2021

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Dr. Rogers on Assessing MRD After Obinutuzumab/Ibrutinib/Venetoclax in CLL

January 4th 2021

Kerry Rogers, MD, discusses the minimal residual disease assessment component of a phase 2 trial evaluating obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Barr on the Need to Develop Novel Therapies in CLL

December 23rd 2020

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Rapid Readouts: Five-Year Analysis of MURANO Study

December 23rd 2020

Dr. Al-Sawaf on the Limitations of Continuous Therapy Administration in CLL

December 22nd 2020

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Modern Paradigm Comprises New Agents and Optimal Patient Selection in CLL

December 18th 2020

Javier L. Munoz, MD, discusses the nuances of choosing treatment options for patients with CLL in the frontline and relapsed/refractory settings, as well as novel therapeutic strategies on the horizon.